A 6 month open-label, flexible-dosage study to assess the safety and effectiveness of PROVIGIL® (Modafinil) treatment in children and adolescents with excessive sleepiness associated with narcolepsy or obstructive sleep apnea/hypopnea.
100 项与 Cephalon Europe Ltd. 相关的临床结果
0 项与 Cephalon Europe Ltd. 相关的专利(医药)
100 项与 Cephalon Europe Ltd. 相关的药物交易
100 项与 Cephalon Europe Ltd. 相关的转化医学